Progress in RA genetics, pathology and therapy

Nature Reviews Rheumatology

Volumn 9, Issue 2, 2013, Pages 70-72

  Van Vollenhoven, Ronald F ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; HLA B ANTIGEN; HLA DP ANTIGEN; HLA DR ANTIGEN; INFLIXIMAB; MAJOR HISTOCOMPATIBILITY ANTIGEN; METHOTREXATE; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; TOFACITINIB; ENZYME INHIBITOR; HLA ANTIGEN; PIPERIDINE DERIVATIVE; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ANTIGEN BINDING; DOSE RESPONSE; DRUG APPROVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HLADR GENE; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; RISK FACTOR; TREATMENT INDICATION; DISEASE MANAGEMENT; DRUG ANTAGONISM; GENETIC PREDISPOSITION; GENETICS; PATHOLOGY;

ARTHRITIS, RHEUMATOID; DISEASE MANAGEMENT; ENZYME INHIBITORS; GENETIC PREDISPOSITION TO DISEASE; HLA ANTIGENS; HUMANS; PIPERIDINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES; PYRROLES;

EID: 84873414048     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2012.232     Document Type: Review

References (10)

1. Raychaudhuri, S. et al. Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. Nat. Genet. 44, 291-296 (2012).
2. Harre, U. et al. Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J. Clin. Invest. 122, 1791-1802 (2012).
3. van Vollenhoven, R. F. et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N. Engl. J. Med. 367, 508-519 (2012).
4. Fleischmann, R. et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N. Engl. J. Med. 367, 495-507 (2012).
5. Ajeganova, S., Andersson, M. L. & Hafström, I. Obesity is associated with worse disease severity in rheumatoid arthritis as well as with co-morbidities-a long-term follow-up from disease onset. Arthritis Care Res. (Hoboken) http://dx.doi.org/10.1002/acr.21710.
6. Wolfe, F. & Michaud, K. Effect of body mass index on mortality and clinical status in rheumatoid arthritis. Arthritis Care Res. (Hoboken) 64, 1471-1479 (2012).
7. Stavropoulos-Kalinoglou, A. et al. Anti-tumour necrosis factor α therapy improves insulin sensitivity in normal-weight but not in obese patients with rheumatoid arthritis. Arthritis Res. Ther. 14, R160 (2012).
8. de Jong, P. H. et al. Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2011-201162.
9. Moreland, L. W. et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of early aggressive rheumatoid arthritis trial. Arthritis Rheum. 64, 2824-3285 (2012).
10. van Vollenhoven, R. F. et al. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. Lancet 379, 1712-1720 (2012).